Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
- PMID: 18483355
- DOI: 10.1158/1078-0432.CCR-07-2248
Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
Abstract
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors gefitinib and erlotinib are effective therapies for non-small cell lung cancer patients whose tumors harbor somatic mutations in EGFR. All patients, however, ultimately develop resistance to these agents. Thus, there is a great need to understand how patients become resistant to develop effective therapies for these cancers. Studies over the last few years have identified two different EGFR tyrosine kinase inhibitor resistance mechanisms, a secondary mutation in EGFR, EGFR 790M, and amplification of the MET oncogene. These findings have led to clinical trials using newly designed targeted therapies that can overcome these resistance mechanisms and have shown promise in laboratory studies. Ongoing research efforts will likely continue to identify additional resistance mechanisms, and these findings will hopefully translate into effective therapies for non-small cell lung cancer patients.
Similar articles
-
Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.Jpn J Clin Oncol. 2012 Jun;42(6):528-33. doi: 10.1093/jjco/hys042. Epub 2012 Mar 28. Jpn J Clin Oncol. 2012. PMID: 22457323
-
Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.Mol Cancer Ther. 2012 Oct;11(10):2149-57. doi: 10.1158/1535-7163.MCT-12-0195. Epub 2012 Jul 25. Mol Cancer Ther. 2012. PMID: 22844075
-
Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors.Respir Investig. 2014 Mar;52(2):82-91. doi: 10.1016/j.resinv.2013.07.007. Epub 2013 Aug 30. Respir Investig. 2014. PMID: 24636263 Review.
-
Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors and new therapeutic perspectives in non small cell lung cancer.Curr Drug Targets. 2011 Jun;12(6):922-33. doi: 10.2174/138945011795528958. Curr Drug Targets. 2011. PMID: 21443472 Review.
-
Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics.J Oncol Pharm Pract. 2016 Jun;22(3):461-76. doi: 10.1177/1078155215577810. Epub 2015 Apr 8. J Oncol Pharm Pract. 2016. PMID: 25855240 Review.
Cited by
-
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines.Mol Cancer. 2012 Dec 12;11:91. doi: 10.1186/1476-4598-11-91. Mol Cancer. 2012. PMID: 23234355 Free PMC article.
-
Relevance of MET activation and genetic alterations of KRAS and E-cadherin for cetuximab sensitivity of gastric cancer cell lines.J Cancer Res Clin Oncol. 2012 May;138(5):843-58. doi: 10.1007/s00432-011-1128-4. J Cancer Res Clin Oncol. 2012. PMID: 22290393
-
Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway.Cancer Res. 2013 Jan 15;73(2):834-43. doi: 10.1158/0008-5472.CAN-12-2066. Epub 2012 Nov 19. Cancer Res. 2013. PMID: 23172312 Free PMC article.
-
PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR.Cancer Res. 2009 Apr 15;69(8):3256-61. doi: 10.1158/0008-5472.CAN-08-4055. Epub 2009 Apr 7. Cancer Res. 2009. PMID: 19351834 Free PMC article.
-
Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells.Clin Cancer Res. 2009 Mar 1;15(5):1585-92. doi: 10.1158/1078-0432.CCR-08-2068. Epub 2009 Feb 3. Clin Cancer Res. 2009. PMID: 19190133 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous